在口服葡萄糖耐受性测试中,非浸泡血压模式和不同的葡萄糖代谢配置之间存在关联
Valentino Condoleo1, Raffaele Maio1, Velia Cassano2
1Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Campus Universitario "S. Venuta", Viale Europa-Località Germaneto, 88100, Catanzaro, Italy.
Internal and emergency medicine
|October 6, 2023
概括
高血压和葡萄糖代谢是相关的. 在患有正常葡萄糖耐受性和口服葡萄糖耐受性测试 (OGTT) 期间1小时葡萄糖水平升高的患者中常见的非滴血血压 (BP) 模式与心血管风险增加有关.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 高血压研究 高血压研究
背景情况:
- 非生理性血压 (BP) 昼夜模式与器官损伤和心血管 (CV) 事件的增加有关.
- 了解血压模式和葡萄糖代谢之间的关系对于管理心血管风险至关重要.
研究的目的:
- 在口服葡萄糖耐受性测试 (OGTT) 后,研究昼夜血压模式和葡萄糖代谢表型之间的关联.
- 确定特定的葡萄糖耐受性类别,与高血压患者的异常血压下降模式相关.
主要方法:
- 招募了810名高血压的白人患者,接受了OGTT,实验室测试和24小时的门诊血压监测 (ABPM).
- 将患者分为四个BP浸泡类别:浸泡者,非浸泡者,极端浸泡者和反向浸泡者.
- 利用后勤回归来分析葡萄糖水平,马苏达指数,估计的膜过率 (e-GFR) 和BP浸泡模式之间的关系.
主要成果:
- 与其他NGT和降低葡萄糖耐受性 (IGT) 组相比,在2型糖尿病 (T2DM) (52.6%) 和具有正常葡萄糖耐受性 (NGT) 和1小时葡萄糖≥155 mg/dL (36.4%) 的患者中,非浸泡者的比例显著更高.
- 具有NGT≥155 mg/dL和T2DM的患者显示出较低比例的.
- 在OGTT期间1小时血糖升高 (≥155 mg/dL) 将病理性夜间血压下降的风险增加了74% (OR=1.740).
- 松田指数和e-GFR的改善与异常血压下降的风险降低有关.
结论:
- 在新诊断的高血压患者中,昼夜血压概况和改变的血糖反应之间存在显著的关联.
- 具体来说,NGT和OGTT后1小时高血糖水平的个体表现出非低血压模式.
- 这一发现可能部分解释了在这个患者群体中观察到的心血管风险升高.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
561
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
561
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Hypoglycemia and Glucagon
277
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
277
Glucose Homeostasis: Regulation of Blood Glucose
1.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.7K
Oral Hypoglycemic Agents: Glinides
166
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
166
Oral Hypoglycemic Agents: Biguanides and Glitazones
215
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
215


